• Dry Cracked Skin
  • General Dermatology
  • Impetigo
  • Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Surgery
  • Melasma
  • NP and PA
  • Anti-Aging
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Inflamed Skin

The Weekly Roundup: November 26-December 1


ICYMI, this week we had articles about the FDA granting priority review of Abeona's pz-cel BLA for recessive DEB, end-of-the-month highlights from the November issue and supplement of Dermatology Times, the FDA accepting Arcutis' sNDA of roflumilast cream 0.15% for AD, and more.

New International Vitiligo Task Force Recommendations

Recently, a significant breakthrough was achieved when 42 international vitiligo experts and 4 patient representatives collaborated and developed a consensus management strategy for vitiligo.

Frontline Forum Part 3: Topical Therapy for Corticosteroid-Responsive Dermatoses

Experts discuss enhancing patient outcomes, comparing clobetasol cream concentrations, and more.

Derm In The News: November 19-25

Keep up with the latest headlines in dermatology from the past week, including new research related to eczema and itch linked to bacteria, a new drug developed for melanoma and lung cancer demonstrating potential in the treatment of cSCC, and more.

Pointers With Portela: Risks of Having Moles Lasered Off

In this week’s Pointers With Portela, the 208SkinDoc reviews on his podcast why it's dangerous to have moles lasered off before taking a biopsy.

Why Dermatologists Are Not Average Investors

This article compares physicians in general to average US investors in several key areas and examines how these factors affect a dermatologist’s approach to investing and wealth management.

AD Case Study: Topical Steroids Are Not Cutting It

Ted Lain, MD, MBA, moderated a discussion to share strategies to optimize treatment sequencing, reevaluate long-term management, understand barriers to novel therapies, promote prior authorization integration, and diversify treatment areas.

FDA Grants Priority Review of Abeona’s Pz-cel BLA for Recessive DEB

The FDA’s PDUFA target date is May 25, 2024.

I Was in a Hurry, and I Was Sued

As more dermatology clinicians find themselves increasingly exhausted, being in a hurry can lead to legal repercussions.

RPT193 Demonstrates Greater Improvements in Clinical Efficacy Endpoints vs Placebo in Atopic Dermatitis

A phase 1 study found that RPT193 monotherapy led to greater improvements in clinical efficacy than treatment with a placebo.

Social Vulnerability Among Individuals With Truncal-Extremity Melanomas Leads to Detriments in Care and Prognosis

Identifying social determinants in TEM is crucial to eliminating disparities in care, study authors wrote.

Psoriasis and Psoriatic Arthritis Linked to Depression and Functional Impairment

Depression, functional impairment, and worsened quality of life are related in patients with psoriatic disease, according to a recent study.

FDA Accepts sNDA for Arcutis' Roflumilast Cream 0.15% for Atopic Dermatitis, Sets July 2024 PDUFA Date

The sNDA is supported by positive data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials.

Alopecia Areata Linked to Hearing Loss, Study Finds

A recent study linked alopecia areata and the presence of cochlear dysfunction in some patients.

First Real-World Report of Near Complete Response With Cemiplimab in Penile Squamous Cell Carcinoma, Study Confirms

Each of 3 patients treated with cemiplimab achieved a near complete response.

Greater Understanding Necessary in Treatment of Periorbital Facial Necrotizing Fasciitis, Review Argues

With greater understanding of this rare pathology and its signs and symptoms, review authors believe this understanding could prompt early and necessary intervention.

Discovering Dermatology Times: November 2023

Learn more about the in-depth topics covered in the November 2023 print issue of Dermatology Times.

Discovering Dermatology Times: November 2023 Corticosteroid-Responsive Dermatoses Supplement

Learn more about the in-depth topics covered in the November 2023 Frontline Forum corticosteroid-responsive dermatoses supplement of Dermatology Times.

Samsung Bioepis Receives US License Date for Proposed Ustekinumab Biosimilar, SB17

The US license period will start on February 22, 2025.

Dual-Wavelength Laser Technology Demonstrates Promise in Atrophic Acne Scar Management

The technology combines the irradiation of two wavelengths at 10,600 nm and 1540 nm.

POLL: Which of the Following Conditions Is Commonly Associated With Secondary Hyperhidrosis?

Click here to answer this week's poll for Hyperhidrosis Awareness Month.

Bemcentinib Plus SOC Is Well Tolerated, But Does Not Improve Efficacy in Metastatic Melanoma

The addition of bemcentinib to the standard-of-care therapies of pembrolizumab or dabrafenib plus trametinib was well tolerated in patients with metastatic melanoma; however, it did not lead to improvements in overall response rate, progression-free survival, or overall survival vs SOC alone.

Reviewing Dermatologic Manifestations of HIV Infection and Acquired Immunodeficiency Syndrome

This World Aids Day, review the common dermatologic manifestations of AIDS and HIV infection.

Melasma Significantly Impacts Quality of Life Among Patients With Darker Skin Types

Investigators also developed a MELASQoL model using 4 predictors of quality of life impacts in patients with melasma.

To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.

Related Videos
© 2024 MJH Life Sciences

All rights reserved.